These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 28475698)
1. The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research. Roy NS; Wei Y; Kuklinski E; Asbell PA Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO1-BIO19. PubMed ID: 28475698 [TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
3. Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Wei Y; Gadaria-Rathod N; Epstein S; Asbell P Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8327-36. PubMed ID: 24204044 [TBL] [Abstract][Full Text] [Related]
4. Development and content validity assessment of the Dry Eye Disease Questionnaire in patients with dry eye disease, meibomian gland dysfunction, and Sjögren's syndrome dry eye disease. Sloesen B; Young A; Forde K; Hodson N; Bentley S; Walsh O; Naujoks C; O'Brien P; Sharma G J Patient Rep Outcomes; 2023 Jul; 7(1):64. PubMed ID: 37405617 [TBL] [Abstract][Full Text] [Related]
5. Defining Dry Eye from a Clinical Perspective. Tsubota K; Pflugfelder SC; Liu Z; Baudouin C; Kim HM; Messmer EM; Kruse F; Liang L; Carreno-Galeano JT; Rolando M; Yokoi N; Kinoshita S; Dana R Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291796 [TBL] [Abstract][Full Text] [Related]
6. LipiFlow for the treatment of dry eye disease. Pucker AD; Yim TW; Rueff E; Ngo W; Tichenor AA; Conto JE Cochrane Database Syst Rev; 2024 Feb; 2(2):CD015448. PubMed ID: 38314898 [TBL] [Abstract][Full Text] [Related]
7. Tear Proteomics Study of Dry Eye Disease: Which Eye Do You Adopt as the Representative Eye for the Study? Kuo MT; Fang PC; Kuo SF; Chen A; Huang YT Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401599 [TBL] [Abstract][Full Text] [Related]
8. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
9. Tear Proteomics Approach to Monitoring Sjögren Syndrome or Dry Eye Disease. Kuo MT; Fang PC; Chao TL; Chen A; Lai YH; Huang YT; Tseng CY Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010136 [TBL] [Abstract][Full Text] [Related]
11. Molecular and cellular biomarkers in dry eye disease and ocular allergy. Enríquez-de-Salamanca A; Bonini S; Calonge M Curr Opin Allergy Clin Immunol; 2012 Oct; 12(5):523-33. PubMed ID: 22895048 [TBL] [Abstract][Full Text] [Related]
12. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Sheppard J; Shen Lee B; Periman LM Ann Med; 2023 Dec; 55(1):241-252. PubMed ID: 36576348 [TBL] [Abstract][Full Text] [Related]
13. Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease. Brignole-Baudouin F; Riancho L; Ismail D; Deniaud M; Amrane M; Baudouin C Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2438-2448. PubMed ID: 28448672 [TBL] [Abstract][Full Text] [Related]
14. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye. McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427 [TBL] [Abstract][Full Text] [Related]